International Journal of Pharmacognosy and Herbal Drug Technology (IJPHDT)
ISSN: 3049-1630 | Vol. 03, Issue 05, May-August-2026 | pp. 63-81

ORIGINAL ARTICLE https://www.aktpublication.com/index.php/ijphdt

Pharmacognostic and Phytochemical Investigation of *Camellia sinensis* for Anti-Obesity Activity in Metabolic Syndrome

Srikumar Chakravarthi[1*], Natalie Wong Yong Xin[2], Sheba R David[3], Mohammad Nazmul Hasan Maziz[4], Rajan Rajabalaya[5], Jestin Chellian[5]

[1]Faculty of Medicine, Nursing and Health Sciences, SEGi University, Selangor, Malaysia
[2]M Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Selangor, Malaysia.
[3]School of Pharmacy, University of Wyoming, USA
[4]Graduate School of Medicine, Perdana University, Kuala Lumpur, Malaysia
[5]PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Brunei Darussalam

***Corresponding Author E-mail: srikumarc@segi.edu.my**

Abstract:

Metabolic syndrome (MetS) is a cluster of cardiometabolic abnormalities including central obesity, insulin resistance, dyslipidemia, and hypertension that markedly increases the risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease. Lifestyle modification remains the cornerstone of management, but there is growing interest in adjunctive nutraceutical and phytopharmacological approaches capable of safely addressing multiple MetS components. Green tea, derived from the leaves of *Camellia sinensis* (family Theaceae), is one of the most widely consumed beverages worldwide and is rich in polyphenolic catechins, primarily (−)-epigallocatechin-3-gallate (EGCG), which have been extensively investigated for anti-obesity and metabolic benefits. This review provides a pharmacognostic and phytochemical perspective on *C. sinensis* as an anti-obesity agent in the context of MetS. Pharmacognostic sections summarize macroscopic and microscopic diagnostic features, physicochemical constants, and quality-control parameters for different tea types (green, white, oolong) based on recent standardization studies. Phytochemical sections describe major and minor constituents, with emphasis on catechins, caffeine, theaflavins, thearubigins, and other phenolics, and their quantitative variation by cultivar, processing, and extraction method. Mechanistic evidence from in vitro, animal, and human intervention studies is synthesized to delineate how tea polyphenols modulate body weight, adiposity, lipid and glucose metabolism, blood pressure, and inflammation. Proposed mechanisms include increased energy expenditure and fat oxidation via catechin–caffeine-induced sympathetic stimulation; inhibition of digestive enzymes and nutrient absorption; modulation of lipid metabolism and de novo lipogenesis; activation of AMP-activated protein kinase (AMPK); improvement of insulin signaling; regulation of adipokine secretion; and remodeling of gut microbiota composition and function. Pharmacokinetic, safety, and formulation aspects are discussed, alongside limitations and variability in clinical trial outcomes. The review concludes that standardized *C. sinensis* preparations, especially catechin-enriched green tea extracts, represent promising multi-target adjuncts for obesity and MetS management, while highlighting the need for rigorous pharmacognostic standardization, dose–response characterization, and biomarker-driven clinical trials.

Keyword: *Camellia sinensis*; Green tea; Metabolic syndrome; Catechins; Anti-obesity activity; Gut microbiota; Lipid metabolism; AMPK signaling

Received: May 10, 2026 **Revised: June 21, 2026** **Accepted: July 25, 2026** **Published: August 03, 2026**

DOI: https://doi.org/10.64063/3049-1630.vol3.issue5.000250

https://ijphdt.com

1. Introduction

1.1 Metabolic syndrome and obesity

MetS is defined by co-occurrence of abdominal obesity, impaired glucose regulation, elevated blood pressure, high triglycerides, and low high-density lipoprotein cholesterol, and is associated with a two- to fivefold increased risk of cardiovascular events and T2DM. Central obesity, often assessed by waist circumference, is a central component of this syndrome and reflects excess visceral adiposity, which drives insulin resistance, dyslipidemia, and low-grade inflammation through altered adipokine secretion and ectopic lipid deposition in liver and muscle[1].

Modern obesogenic lifestyles characterized by excessive caloric intake, high-fat/high-sugar diets, and physical inactivity are the principal drivers of the MetS epidemic. Pharmacological options for obesity and MetS are limited by modest efficacy, adverse effects, and cost, prompting interest in complementary nutraceuticals and functional foods that can safely address multiple pathophysiological axes. Tea polyphenols from *C. sinensis* are among the most intensively investigated candidates in this context[2-3].

1.2 *Camellia sinensis* as a metabolic modulator

Tea, prepared from processed leaves of *C. sinensis*, is the second most consumed beverage globally after water and has a long history of use both as a refreshment and as a medicinal infusion in East Asian cultures. Depending on processing—degree of enzymatic oxidation of catechins—tea is categorized into green (unfermented), white (minimally processed buds and young leaves), oolong (partially fermented), and black (fully fermented) types, each with distinct phytochemical profiles[4-5.]

Green tea, in which catechins are preserved via pan-firing or steaming, has attracted greatest interest for weight control and MetS because of its high content of EGCG and other catechins such as epigallocatechin (EGC), epicatechin (EC), and epicatechin gallate (ECG). Numerous mechanistic and clinical studies indicate that daily consumption of catechin-rich green tea or extracts can reduce body weight and fat mass and improve metabolic risk markers in overweight or obese individuals, although results vary across studies[6-7].

This article integrates pharmacognostic, phytochemical, and pharmacological data on *C. sinensis* relevant to anti-obesity effects in MetS, emphasizing how proper botanical identification, standardization, and phytochemical characterization underpin reproducible therapeutic outcomes.

2. Pharmacognostic Characterization of *Camellia sinensis*

2.1 Botanical identity and taxonomy

C. sinensis (L.) Kuntze is an evergreen shrub or small tree belonging to the family Theaceae. Two main botanical varieties are generally recognized: *C. sinensis* var. *sinensis*, with small leaves tolerant of cool climates, and var. *assamica*, with larger leaves prevalent in tropical regions. Morphologically, the plant bears alternate, lanceolate to elliptic leaves with serrated margins, short petioles, and a glossy dark green upper surface; fragrant white bisexual flowers with 5–7 petals arise singly or in clusters, followed by tri-locular capsules containing 1–3 seeds[8].

Accurate taxonomic identification is essential for pharmacognostic standardization, especially given the proliferation of herbal products and potential adulteration with related species or other Camellia taxa. Morphological traits, combined with microscopic, chromatographic, and DNA-barcoding methods, enhance assurance of botanical authenticity[9-10]. **(** Table 1)

Table 1. Pharmacognostic Characteristics of *Camellia sinensis* Leaves

Parameter	Description	Diagnostic Significance
Botanical name	*Camellia sinensis* (L.) Kuntze	Authentic plant identification
Family	Theaceae	Taxonomic classification
Leaf morphology	Lanceolate to elliptic leaves with serrated margins	Key macroscopic feature
Leaf surface	Glossy dark green upper surface	Helps distinguish fresh leaves
Flower characteristics	White bisexual flowers with 5–7 petals	Botanical identification marker
Stomata type	Anomocytic stomata	Microscopic diagnostic feature
Trichomes	Present depending on leaf age	Supports powder identification

Calcium oxalate crystals	Frequently observed	Microscopic authentication marker
Moisture content	~2.2%	Indicates storage stability
Total ash value	~7.78%	Measures total mineral content
Acid-insoluble ash	~1.6%	Indicates contamination level
Extractive values	Water and alcohol soluble fractions	Determines phytochemical yield

2.2 Macroscopic and organoleptic features of leaves and commercial teas

Macroscopic evaluation of dried tea leaves considers shape, size, color, odor, and texture. Green tea leaves typically appear as twisted or rolled fragments of varying sizes, colored green to dark green, with a characteristic astringent taste and grassy aroma; white tea consists of young buds covered with silvery hairs and has a light green-brown hue; black tea particles are dark brown to black with a strong aromatic odor[11].

A pharmacognostic standardization study on *C. sinensis* plant parts reported specific macroscopic descriptors for stems, leaves, and seeds, providing reference parameters for quality control in raw material procurement. Organoleptic features, while subjective, assist in preliminary identification and detection of gross adulteration[12].

2.3 Microscopic characteristics and powder analysis

Microscopic examination of fresh and powdered leaves reveals diagnostic anatomical features. Transverse sections show a dorsiventral leaf structure with upper and lower epidermis, palisade and spongy parenchyma, and collateral vascular bundles; thick cuticle, wavy anticlinal walls, and anomocytic stomata are typical. Calcium oxalate crystals, sclereids, and abundant trichomes may be present depending on the leaf age and variety[13].

Powder microscopy of tea leaf powder reveals fragments of epidermis with straight to wavy walls, anomocytic stomata, spiral and annular xylem vessels, fibers, and palisade cells associated with chloroplasts, which serve as diagnostic markers. Fluorescence analysis under UV light after treatment with various reagents can provide additional fingerprint features useful for detecting adulterants or substitutions[14].

2.4 Physicochemical parameters and quality control

Standard physicochemical parameters such as moisture content, total ash, acid-insoluble ash, water-soluble ash, extractive values (water, alcohol, etc.), and foreign organic matter are used to assess purity and quality of tea leaves. A recent comparative study reported total ash value, acid-insoluble ash, water-soluble ash, moisture content, and foreign matter for *C. sinensis* leaves as approximately 7.78%, 1.6%, 8%, 2.2%, and 0.21%, respectively, indicating good quality and low contamination[15].

Such parameters, combined with limits for pesticide residues, heavy metals, and microbial load, form the basis for pharmacopoeial monographs and regulatory standards. For specialized extracts used in clinical trials, additional quality metrics are needed, including catechin and caffeine content determined by HPLC or HPTLC[16-17].

2.5 Chromatographic fingerprinting and chemometrics

Chromatographic techniques, particularly HPLC and HPTLC, are widely applied to generate chemical fingerprints of tea extracts and to quantify marker constituents such as EGCG, EGC, EC, and ECG. HPTLC fingerprinting of white tea ethanolic extracts identified multiple peaks corresponding to major catechins and caffeine, enabling differentiation of authentic material from adulterant species[18-19].

Chemometric approaches, including principal component analysis and cluster analysis based on chromatographic profiles, can discriminate geographic origin, cultivar, and processing type of *C. sinensis* and correlate chemical profiles with bioactivity, providing powerful tools for quality assurance in anti-obesity product development.

3. Phytochemical Constituents Relevant to Anti-Obesity Activity

3.1 Catechins and other flavan-3-ols

Tea catechins are a type of flavan-3-ols, the major components being EGCG (50–60% of total catechins), EGC, EC and ECG, in addition to small amounts of gallocatechin (GC) and catechin. They have several hydroxyl groups and, in gallated options, a member concerned with strong antioxidant activity and protein binding flooring. Catechin levels are highest in young leaves and buds and decrease with more fermentation during processing, so green and white teas have considerably higher amounts of catechins than black tea[20].

Catechins are regarded as key mediators of the anti-obesity and metabolic effects of tea, modulating energy expenditure, fat oxidation, lipid absorption, and glucose homeostasis via multiple molecular targets which will be summarized in subsequent sections[21]. (Table 2)

Table 2. Major Phytochemicals of *Camellia sinensis* and Their Anti-Obesity Mechanisms

Phytochemical	Chemical Class	Major Mechanism	Therapeutic Effect
EGCG (Epigallocatechin gallate)	Catechin	AMPK activation	Increased fat oxidation
EGC (Epigallocatechin)	Catechin	Antioxidant activity	Reduced oxidative stress
EC (Epicatechin)	Catechin	Lipid metabolism modulation	Reduced triglycerides
ECG (Epicatechin gallate)	Catechin	Enzyme inhibition	Reduced lipid absorption
Caffeine	Methylxanthine	Sympathetic stimulation	Increased thermogenesis
Theaflavins	Polyphenols	Lipase inhibition	Reduced lipid digestion
Theanine	Amino acid	Neuro-metabolic modulation	Appetite regulation
Phenolic acids	Polyphenols	Anti-inflammatory action	Improved insulin sensitivity
Tea polysaccharides	Carbohydrates	Gut microbiota modulation	Improved metabolic health

3.2 Caffeine and other xanthines

In addition to catechins, C. sinensis leaves also contain methylxanthines from the caffeine family that includes theobromine and theophylline; these alkaloids are responsible for stimulant effects and may interact with catechins in metabolic regulation. (1) Caffeine is an antagonist of the adenosine receptor and inhibits phosphodiesterase, leading to an increase in intracellular cAMP which stimulates sympathetic nervous system activity, thermogenesis and lipolysis[21].

It is therefore vital to consider the potential for synergistic interactions between catechins and caffeine, which collectively elevate energy expenditure and fat oxidation beyond that predicted by intake of one compound alone, when formulating catechin-enriched but caffeine-moderated formulations[22].

3.3 Theaflavins, thearubigins, and black tea polyphenols

Black tea fermentation involves enzymatic oxidation of catechins catalyzed by polyphenol oxidase and peroxidase, resulting in the formation of complex polymeric pigments known as theaflavins (TFs) and thearubigins that contribute to black tea coloring and flavor compounds. TFs like theaflavin-3-gallate and theaflavin-3,3′-digallate exhibit strong antioxidant and enzymatic inhibitory activities as well as affect lipid absorption and metabolism[23], but their anti-obesity effects seem less intensively studied compared to catechins.

3.4 Other bioactives: theanine, phenolic acids, saponins, and polysaccharides

Non-protein amino acid theanine (γ-glutamylethylamide) is responsible for umami taste and has neuroactive, stress-modulating properties that may promote indirect effects on eating behavior and metabolic regulation. The phenolic acids (e.g., gallic, chlorogenic), saponins, and polysaccharides present in C. sinensis also possesses antioxidant-, hypolipidemic-, and immunomodulatory effects that may contribute to global anti-MetS activities[24].

Other biologically active compounds found in tea polysaccharides have also been shown to reduce blood glucose and lipids in animal models, possibly by modulating gut microbiota and bile acid metabolism, indicating they may provide adjunctive benefits along with catechins[25.]

4. Mechanistic Basis of Anti-Obesity and Anti-MetS Effects

4.1 Effects on energy expenditure and fat oxidation

A mechanistic review of the anti-obesity effects of green tea catechins summarizes evidence suggesting that consumption doses within a range of 270–1200 mg/day GTC in human trials could modestly reduce body weight and body fat [56]. A leading hypothesis is that catechins, and especially EGCG, inibits the enzyme catechol-O-methyltransferase (COMT), so norepinephrine lingers longer and continues to stimulate thermogenesis and fat oxidation, particularly when consumed with caffeine[26.]

Catechin–caffeine mixtures increase 24-hour energy expenditure and fat oxidation relative to caffeine or placebo in controlled clinical trials, effects ascribed to raised norepinephrine levels and augmented β-adrenergic stimulation of brown adipose tissue and skeletal muscle. These findings are supported by animal experiments showing upregulation of genes related to fatty acid oxidation such as CPT1 and UCPs and downregulation of lipogenic pathways in the liver and adipose tissue after treatment with green tea or EGCG[27].

4.2 Modulation of lipid absorption and metabolism

Catechins bind to dietary lipids and digestive enzymes reducing lipid absorption. In vitro studies show green tea catechins to inhibit pancreatic lipase, a key enzyme of triglyceride digestion; they also impair micellar solubilization of cholesterol. EGCG and related catechins also decrease

intestinal expression of fatty acid transporter CD36 (a long-chain fatty acid uptake protein) and Niemann–Pick C1-like 1 (NPC1L1, a cholesterol transport protein), decreasing lipid uptake even more[28].

In animal models of dietary obesity, supplementation with green tea or EGCG reduces body weight gain, hepatic triglyceride deposition and serum lipids, at least in part through the upregulation of hepatic fatty acid oxidation as well as downregulation of lipogenic genes (FAS, SREBP-1c and ACC). Combinations of EGCG with either taurine or resistant starch elicited synergistic interactions to form complexes that more effectively alleviate lipid metabolic disorders via modulation of PPARα, FAS, and gut microbiota–short-chain fatty acid axes[29].

4.3 AMPK activation and glucose homeostasis

AMPK acts as a master energy sensor that activates catabolic pathways and suppress ds anabolic pathways under conditions of low cellular energy. AMPK activation in liver, muscle, adipose tissue and intestine promotes fatty acid oxidation, glucose uptake, inhibits gluconeogenesis/lipogenesis and increases insulin sensitivity.

Experimental studies demonstrate that EGCG activate AMPK in hepatocytes and skeletal muscle, resulting in the increased fatty acids oxidation and glucose uptake, but these effects are reduced when AMPK signaling is inhibited. In mouse models of obesity and insulin resistance, green tea and EGCG lower fasting glucose and insulin levels, enhance insulin signaling, and reduce hepatic steatosis, with concomitant increases in AMPK phosphorylation. The role of intestinal AMPK to modulate gut microbiota composition and metabolic outcomes has also been demonstrated, thus providing a potential link for catechin-induced intestinal AMPK activation with gut microbiota modulation and improved MetS-related parameters in our study[30].

4.4 Gut microbiota modulation

Increasing evidence indicates that the gut microbiome plays an important role in regulating energy balance, adiposity and systemic inflammation, with dysbiosis contributing to obesity and MetS. Tea polyphenols (particularly EGCG) are weakly absorbed in the upper intestine and hence reach the colon where they interact extensively with gut microbes, undergoing biotransformation into smaller phenolic metabolites as well as modifying microbial composition[31].

Recent reviews describe a bidirectional influence whereby EGCG composes gut microbiome's profile for higher abundance of beneficial genera (i.e., Akkermansia, Bifidobacterium) and lower obesity-related taxa while microbial active compounds from EGCG contribute to benefits in inflammation and metabolism. In animal studies, formulations with EGCG rebalance microbiota, boost short-chain fatty acid production and ameliorate MetS parameters; synergistic compounds (e.g., taurine or starch) are improving these effects[32].

4.5 Effects on appetite regulation and adipokines

Direct appetite suppression effects of tea catechins are less consistent, but several human studies have found lower subjective appetite and altered levels of the hormones ghrelin and leptin after ingestion of green tea catechin. Catechins and EGCG might involve gut-brain in the signaling pathway by mediating hormones from gut (GLP-1, PYY) via vagal nerve [17], although underlying mechanisms still warrant researched attention[33].

They also regulate adipokines, with animal studies showing increased adiponectin and decreased leptin and resistin driven by green tea and EGCG, findings linked to enhanced insulin sensitivity and anti-inflammatory changes[34].

4.6 Antioxidant and anti-inflammatory actions

MetS and obesity are associated with oxidative stress and low-grade chronic inflammation starting from adipose tissue, liver, and vascular endothelium. Tea polyphenols are powerful antioxidants that have been shown to effectively scavenge reactive oxygen species, chelate metal ions and increase the expression of endogenous antioxidant enzymes (SOD, catalase and glutathione peroxidase). [35]

EGCG suppresses the NF-κB pathway and decreases pro-inflammatory cytokines (TNF-α, IL-6, MCP-1) and adhesion molecule expression in adipose tissue, liver and vascular cells. This contributes to the mitigation of insulin resistance, endothelial dysfunction and atherogenesis in models of MetS[36].

5. Evidence from Animal Models and In Vitro Studies

5.1 Laboratory studies on MetS prevention

Based on a series of studies conducted in cell culture and animal models, the authors concluded that gree-n tea and EGCG can protect against weight gain and features of MetS [179]. Compared with control high-fat diets, EGCG supplementation generally reduces body weight gain, visceral fat accumulation, glucose intolerance, fasting insulin level, blood pressure and improves the lipid profile[37].

Mechanistically, these benefits are associated with decreased lipogenesis in the liver and increased oxidation of fatty acids; activated AMP-activated protein kinase (AMPK); reduced oxidative stress; and attenuated inflammatory marker expression in fat depots and vasculature. In vitro studies using adipocyte and hepatocyte cultures indicated that EGCG inhibited adipogenesis through downregulation of peroxisome proliferator-activated receptor (PPAR)γ and CCAAT/enhancer binding protein (C/EBP)α, along with stimulating lipolysis and β-oxidation in addition to inhibiting gluconeogenic enzymes in hepatocytes[38].

5.2 Synergistic formulations and complexes

Recent research has focused on complexes of EGCG with other nutraceuticals or food matrices for increased stability, bioavailability, and efficacy. An EGCG–taurine combination, for example, was more effective than each single compound in modulating gut microbiota and PPARα/FAS signaling that improved lipid metabolic disturbances in high-fat diet-fed mice. Most encouraging was a study showing that a complex of lotus seed starch–EGCG can regulate obesity through the gut microbiota–SCFA–metabolism axis, reinforcing the idea that targeting delivery matrix dramatically affects metabolic outcomes [39]

These results of pharmacognostic and formulation aspects—like the resemblance between tea extracts co-constituents, food matrices significantly determine anti-obesity efficacy in a product design.

6. Clinical Evidence for Anti-Obesity and Anti-MetS Effects

6.1 Weight reduction and body composition

A number of randomized controlled trials have examined the impact of green tea or catechin enriched beverages on weight loss in overweight or obese adults. A mechanistic review describing 11 trials reported a beneficial impact of green tea catechins (270–1200 mg/day plus usually 150 mg/day caffeine) on body weight (−1–3 kg) and body fat percentage (−1–4%) over 12–13 weeks vs. control beverages, albeit with response variability[40].

Sustained and coupled with lifestyle modification, these modest effect sizes are therefore clinically relevant. Subgroup analyses imply that low habitual caffeine consumers and some genotypes (e.g., COMT, ADRB2 variants) are more sensitive to catechin–caffeine synergy on weight loss.

6.2 Metabolic risk factors

Clinical studies investigating the components of MetS indicate that supplementation with green tea or EGCG can lead to modest improvements in lipid profiles (reduced LDL cholesterol and triglycerides, increased HDL cholesterol), blood pressure, and insulin sensitivity (HOMA-IR) measures and fasting glucose levels only in some populations[41].

However, results are heterogeneous depending on baseline metabolic status, dose and duration of intervention, catechin/caffeine content and lifestyle. However, one narrative review finds that tea polyphenol intake universally has small but beneficial effects on body weight, glucose homeostasis, blood pressure and inflammatory markers and could be considered as an adjunctive strategy for MetS management[42].

6.3 Safety and tolerability

C. sinensis is considered safe for most people at usual dietary levels (up to 3–4 tsp cups of tea/day). Hepatotoxicity with high-dose catechin extracts (≥800–1000 mg/day EGCG) on rare occasions has

prompted regulatory agencies to recommend upper intake limits and precautionary labeling. Common nonserious adverse effects associated with caffeine are gastrointestinal upset and insomnia [43].Therefore, pharmacognostically standardized extracts of known catechin and caffeine content (given in evidence-based dose ranges) are critical for establishing the balance between efficacy and safety for MetS populations, specifically those that involve comorbid liver disease or concurrent hepatotoxic drugs.

7. Pharmacognostic and Formulation Considerations for Anti-Obesity Products

7.1 Selection of tea type and extraction method

Both green and white teas are selected for anti-obesity and MetS indications owing to higher catechin content and lower oxidation. Aqueous ethanol or water extractions at controlled temperatures maximize catechin yield and minimize degradation. Ethanolic preparations of white tea leaves have been standardized pharmacognostically to ensure consistent catechin profile and antioxidant potentials[44].

And, catechin-rich extracts without caffeine would be ideal for individuals sensitive to that compound, even if a little thermogenic synergy could be lost. To modify catechin/caffeine ratios and remove impurities, supercritical CO_2 extraction and membrane separation technologies are being developed[45].

7.2 Standardization markers and quality control

The pharmacognostic standardization of C. sinensis anti-obesity products must be established, which should include botanical identity confirmation and physicochemical parameters (quantitative specification for total catechins, individual catechin content (EGCG, EGC, EC and ECG), caffeine and moisture content). HPLC or UPLC chromatograms provide fingerprints for individual batches that can be linked to bioactivity[46].

Limits for heavy metals, pesticide residues, aflatoxins and microbiological contamination also need to comply with pharmacopeial and regulatory requirements. The shelf-life and suitable packaging (e.g. light- and humidity protection) which maintain catechin integrity are established by stability studies under both accelerated and real-time conditions[47].

7.3 Delivery systems to enhance bioavailability

Oral bioavailability of EGCG is limited by poor permeability, extensive first-pass metabolism, and efflux by transporters. Various formulation strategies, including nanoemulsions, liposomes, polymeric nanoparticles, phospholipid complexes, and co-crystals, have been developed to enhance EGCG stability and absorption, some showing improved metabolic benefits in preclinical models[48]

Complexation of EGCG with starches, proteins, or amino acids can modulate release, protect against gastrointestinal degradation, and facilitate targeted delivery to the colon for microbiota-

mediated actions. These technological advances, informed by pharmacognostic characterization, can substantially influence clinical efficacy[49].

8. Integration with Gut Microbiome and Systems Biology of MetS

8.1 Gut microbiota in metabolic syndrome

Dysbiosis of gut microbiota contributes to obesity and MetS by increasing energy harvest, modulating bile acid metabolism, altering gut permeability and endotoxemia, and influencing host appetite and energy expenditure via the gut–brain axis. Increased Firmicutes-to-Bacteroidetes ratios, depletion of butyrate-producing bacteria, and reduced microbial diversity are frequently observed in obese individuals[50].

Dietary polyphenols such as tea catechins act as prebiotic-like modulators of microbiota, selectively stimulating beneficial taxa and inhibiting pathogenic species, thereby impacting host metabolism and inflammation[51].

8.2 EGCG microbiota interactions

In a 2025 review, the authors provide beneficial examples of synergistic interactions between EGCG and gut microbiota whereby microbes metabolize EGCG into more simplistic phenolic acids with unique bioactivities while EGCG alters the microbial composition and metabolic output. We observed that, in animal models, EGCG supplementation enhanced the abundance of Akkermansia and Lactobacillus in the gut microbiota which contributes to production of short-chain fatty acids further improving metabolic parameters.(-)-Epigallocatechin gallate (EGCG) co-administration with taurine or resistant starch additionally shapes gut microbiota SCFA host metabolic axes, indicating prudent combination with other dietary factors can maximize microbiome-mediated anti-obesity effects[52].

8.3 Systems-level perspectives

Systems biology approaches integrating metabolomics, transcriptomics, and microbiome profiling are beginning to elucidate global networks affected by tea polyphenols. For example, metabolomic analyses show that EGCG alters bile acid profiles, lipid metabolites, and inflammatory mediators, while transcriptomics reveals changes in pathways related to lipid metabolism, oxidative stress, and immune responses[53].

Such holistic data, when combined with pharmacognostic and phytochemical information, can inform precision nutrition strategies in which *C. sinensis* preparations are tailored to individual metabolic phenotypes and microbiome configurations.

9. Limitations, Controversies, and Research Gaps

Despite substantial preclinical and clinical evidence, several limitations and unresolved questions remain regarding the use of *C. sinensis* for anti-obesity and MetS.

1. **Modest effect sizes:** Clinical trials generally show modest reductions in weight and MetS markers, which may be clinically meaningful only when sustained and combined with lifestyle changes. Larger, long-term studies are needed to establish durability of benefits.
2. **Heterogeneity of studies:** Variability in tea type, catechin and caffeine content, dosage, duration, and participant characteristics complicates cross-study comparisons and meta-analyses.
3. **Dose–response relationships:** Optimal doses for maximal benefit without toxicity are not fully established, particularly for high-concentration extracts used as supplements rather than beverages.
4. **Safety at high doses:** Rare cases of hepatotoxicity associated with concentrated green tea extracts necessitate careful monitoring and risk stratification, especially in individuals with pre-existing liver disease.
5. **Interindividual variability:** Genetic polymorphisms affecting catechin metabolism (e.g., COMT, UGTs), caffeine sensitivity, and baseline microbiota composition may influence responsiveness, underscoring the need for personalized approaches.
6. **Standardization challenges:** Differences in cultivation, harvesting, and processing lead to batch-to-batch variation in catechin profiles, requiring rigorous pharmacognostic and chemical standardization for clinical-grade products.

Addressing these gaps will be critical for integrating *C. sinensis* into evidence-based guidelines for MetS management.



Figure 1. Multi-target mechanisms of Camellia sinensis catechins in the management of obesity and metabolic syndrome**.**Major phytochemicals of Camellia sinensis, including EGCG, EGC, EC,

ECG, caffeine, and theaflavins, modulate multiple molecular targets such as AMPK, COMT, pancreatic lipase, CD36, NPC1L1, and NF-κB signaling pathways. These interactions enhance fat oxidation, improve insulin sensitivity, regulate lipid metabolism, modulate gut microbiota, and reduce inflammation, ultimately contributing to reduced adiposity and improved metabolic health.

10. Future Perspectives

Future research on *C. sinensis* and anti-obesity activity in MetS should prioritize:

- **Comprehensive pharmacognostic monographs** that integrate macroscopic, microscopic, physicochemical, and chromatographic reference standards for different tea types and extracts used in clinical research.
- **Well-designed randomized controlled trials** with standardized, quantified catechin/caffeine doses, sufficient sample sizes, and extended follow-up to assess hard outcomes (T2DM incidence, cardiovascular events), not only surrogate markers.
- **Biomarker-driven stratification and response prediction**, including genetic, metabolomic, and microbiome-based predictors of benefit or toxicity
- **Advanced formulation technologies** optimizing bioavailability and targeting of EGCG and other polyphenols while maintaining safety, including nanoformulations and matrix-bound complexes validated in human studies
- **Mechanistic integration of gut–liver–adipose–brain axes**, using systems biology approaches to understand how tea polyphenols reshape network dynamics in MetS and how this can be harnessed for individualized therapy.

11. Conclusion

Pharmacognostic and Phytochemical Studies Supported Anti-Obesity, Anti-MetS Potential of Camellia sinensis. Botanical authenticity and quality control are assured by macroscopic and microscopic characterization, physicochemical constants, and chromatographic fingerprinting; clean understanding of catechins, caffeine, and other phytoconstituents guide formulation design and dose standardization.

A large number of mechanistic, animal and human studies suggest that green tea or its catechins may have small however meaningful impacts on body weight, adiposity, lipid and glucose metabolism, blood pressure and inflammation through increased thermogenesis as well as fat oxidation, inhibition of lipid absorption as well as AMPK activation; improved insulin signaling; modulation of adipocytes' key bioactive products/adipokines related to energy homeostasis; changes in gut microbiota composition. Despite moderate effect sizes, which are affected by the patient's constitution and formulation type, C. sinensis can be considered as a safe and globally accepted adjunctive treatment to lifestyle modification for MetS when administered in doses conforming with safety criteria as standardized beverages or extracts

The integration of pharmacognostic rigor, cutting-edge phytochemistry, systems-level mechanistic studies, and high-quality clinical trials will therefore be critical to fully harness the promise of C. sinensis polyphenols as multi-target natural therapeutics for obesity and MetS.

References

1. Abdelrazek, H., Kilany, O. E., Muhammad, M. A., Tag, H. M., & Abdelazim, A. M. (2018). Black seed thymoquinone improved insulin secretion, hepatic glycogen storage, and oxidative stress in streptozotocin-induced diabetic male Wistar rats. *Oxidative Medicine and Cellular Longevity*, 2018, 8104165. https://doi.org/10.1155/2018/8104165
2. Addepalli, V., & Suryavanshi, S. V. (2018). Catechin attenuates diabetic autonomic neuropathy in streptozotocin-induced diabetic rats. *Biomedicine & Pharmacotherapy*, 108, 1517–1523. https://doi.org/10.1016/j.biopha.2018.09.179
3. Adiban Fard, F., Tork Zahrani, S., Akbarzadeh Bagheban, A., & Mojab, F. (2015). Therapeutic effects of *Nigella sativa* Linn on *Candida albicans* vaginitis. *Archives of Clinical Infectious Diseases*, 10, e22991. https://doi.org/10.5812/archcid.22991
4. Afkhami-Ardekani, M., Kamali-Ardekani, A.-R., & Shojaoddiny-Ardekani, A. (2006). Effects of garlic on serum lipids and blood glucose of type 2 diabetic patients. *International Journal of Diabetes in Developing Countries*, 26(2), 86–88. https://doi.org/10.4103/0973-3930.28279
5. Ajmal Shah, M., Khalil, R., Ul-Haq, Z., & Panichayupakaranant, P. (2017). α-Glucosidase inhibitory effect of rhinacanthins-rich extract from *Rhinacanthus nasutus* leaf and synergistic effect in combination with acarbose. *Journal of Functional Foods*, 36, 325–331. https://doi.org/10.1016/j.jff.2017.07.021
6. Al-Qattan, K. K., Alnaqeeb, M. A., & Ali, M. (1999). The antihypertensive effect of garlic (*Allium sativum*) in the rat two-kidney Goldblatt model. *Journal of Ethnopharmacology*, 66(2), 217–222. https://doi.org/10.1016/S0378-8741(98)00173-1
7. Al-Shiekh, A., Al-Shati, A., & Sarhan, M. (2014). Effect of white tea extract on antioxidant enzyme activities of streptozotocin-induced diabetic rats. *Egyptian Academic Journal of Biological Sciences C: Physiology and Molecular Biology*, 6(2), 17–30. https://doi.org/10.21608/eajbsc.2014.13710
8. Al-Snafi, A. E. (2013). Pharmacological effects of *Allium* species grown in Iraq: An overview. *International Journal of Pharmacy and Health Care Research*, 1(4), 132–147.
9. Alcázar, A., Ballesteros, O., Jurado, J. M., Pablos, F., Martín, M. J., Vilches, J. L., et al. (2007). Differentiation of green, white, black, Oolong, and Pu-Erh teas according to their free amino acid content. *Journal of Agricultural and Food Chemistry*, 55(15), 5960–5965. https://doi.org/10.1021/jf070601a
10. Altun, E., Avci, E., Yildirim, T., & Yildirim, S. (2019). Protective effect of *Nigella sativa* oil on myocardium in streptozotocin-induced diabetic rats. *Acta Endocrinologica*, 15(3), 289–294. https://doi.org/10.4183/aeb.2019.289
11. Alves, M. G., Martins, A. D., Teixeira, N. F., Rato, L., Oliveira, P. F., & Silva, B. M. (2015). White tea consumption improves cardiac glycolytic and oxidative profile of

prediabetic rats. *Journal of Functional Foods*, 14, 102–110. https://doi.org/10.1016/j.jff.2015.01.019

12. Amanzadeh, Z., Zargari, F., & Khalilaria, A. (2020). The effect of aqueous extract of white tea on glucose level and lipid profile in diabetic rats. *Experimental Animal Biology*, 8(4), 123–130.
13. Ansari, Z. M., Nasiruddin, M., Khan, R. A., & Haque, S. F. (2017). Protective role of *Nigella sativa* in diabetic nephropathy: A randomized clinical trial. *Saudi Journal of Kidney Diseases and Transplantation*, 28(1), 9–14. https://doi.org/10.4103/1319-2442.198093
14. Apovian, C. M. (2016). Obesity: Definition, comorbidities, causes, and burden. *American Journal of Managed Care*, 22(Suppl. 7), S176–S185.
15. Ardiana, L., Sauriasari, R., & Elya, B. (2018). Antidiabetic activity studies of white tea (*Camellia sinensis*) ethanolic extracts in streptozotocin-nicotinamide-induced diabetic rats. *Pharmacognosy Journal*, 10(1), 186. https://doi.org/10.5530/pj.2018.1.31
16. Asgary, S., Sahebkar, A., & Goli-Malekabadi, N. (2015). Ameliorative effects of *Nigella sativa* on dyslipidemia. *Journal of Endocrinological Investigation*, 38(10), 1039–1046. https://doi.org/10.1007/s40618-015-0337-0
17. Ashraf, R., Aamir, K., Shaikh, A. R., & Ahmed, T. (2004). Effects of garlic on dyslipidemia in patients with type 2 diabetes mellitus. *Journal of Ayub Medical College Abbottabad*, 17, 60–64.
18. Aslani, N., Entezari, M. H., Askari, G., Maghsoudi, Z., & Maracy, M. R. (2016). Effect of garlic and lemon juice mixture on lipid profile and cardiovascular risk factors in people with moderate hyperlipidaemia: A randomized clinical trial. *International Journal of Preventive Medicine*, 7, 95. https://doi.org/10.4103/2008-7802.187248
19. Atkin, M., Laight, D., & Cummings, M. H. (2016). Effects of garlic extract upon endothelial function, vascular inflammation, oxidative stress, and insulin resistance in adults with type 2 diabetes. *Journal of Diabetes and Its Complications*, 30(4), 723–727. https://doi.org/10.1016/j.jdiacomp.2016.01.003
20. Augusti, K. T. (1975). Studies on the effect of allicin on alloxan diabetes. *Experientia*, 31(11), 1263–1265. https://doi.org/10.1007/BF01945769
21. Awad, A. S., Abd Al Haleem, E. N., El-Bakly, W. M., & Sherief, M. A. (2016). Thymoquinone alleviates nonalcoholic fatty liver disease via suppression of oxidative stress and inflammation. *Naunyn-Schmiedeberg's Archives of Pharmacology*, 389(4), 381–391. https://doi.org/10.1007/s00210-015-1207-1
22. Ayuob, N. N., Abdel-Hamid, A. A. H. M., Helal, G. M. M., & Mubarak, W. A. (2019). Thymoquinone reverses nonalcoholic fatty liver disease associated with experimental hypothyroidism. *Romanian Journal of Morphology and Embryology*, 60(2), 479–486.
23. Badar, A., Kaatabi, H., Bamosa, A., Al-Elq, A., Abou-Hozaifa, B., Lebda, F., et al. (2017). Effect of *Nigella sativa* supplementation over a one-year period on lipid levels, blood pressure, and heart rate in type 2 diabetic patients receiving oral hypoglycemic agents: A nonrandomized clinical trial. *Annals of Saudi Medicine*, 37(1), 56–63. https://doi.org/10.5144/0256-4947.2017.56

24. Balamash, K., Albar, O., Wang, Q., & Ahmed, N. (2012). Effect of Kyolic aged garlic extract on glycaemia, lipidaemia, and oxidative stress in patients with type 2 diabetes mellitus. *Journal of Diabetes Research & Clinical Metabolism*, 1, 18. https://doi.org/10.7243/2050-0866-1-18
25. Balbaa, M., El-Zeftawy, M., Ghareeb, D., Taha, N., & Mandour, A. W. (2016). *Nigella sativa* relieves altered insulin receptor signaling in streptozotocin-induced diabetic rats fed a high-fat diet. *Oxidative Medicine and Cellular Longevity*, 2016, 2492107. https://doi.org/10.1155/2016/2492107
26. Barbagallo, M., & Dominguez, L. J. (2007). Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome, and insulin resistance. *Archives of Biochemistry and Biophysics*, 458(1), 40–47. https://doi.org/10.1016/j.abb.2006.05.007
27. Bathaie, S. Z., & Mousavi, S. Z. (2010). New applications and mechanisms of action of saffron and its important ingredients. *Critical Reviews in Food Science and Nutrition*, 50(8), 761–786. https://doi.org/10.1080/10408390902773003
28. Bayan, L., Koulivand, P. H., & Gorji, A. (2014). Garlic: A review of potential therapeutic effects. *Avicenna Journal of Phytomedicine*, 4(1), 1–14.
29. Benhaddou-Andaloussi, A., Martineau, L. C., Vallerand, D., Haddad, Y., Afshar, A., Settaf, A., et al. (2010). Multiple molecular targets underlie the antidiabetic effect of *Nigella sativa* seed extract in skeletal muscle, adipocyte, and liver cells. *Diabetes, Obesity and Metabolism*, 12(2), 148–157. https://doi.org/10.1111/j.1463-1326.2009.01131.x
30. Bertrand, L., & Lehuen, A. (2019). MAIT cells in metabolic diseases. *Molecular Metabolism*, 27(Suppl.), S114–S121. https://doi.org/10.1016/j.molmet.2019.06.025
31. Boulangé, C. L., Neves, A. L., Chilloux, J., Nicholson, J. K., & Dumas, M. E. (2016). Impact of the gut microbiota on inflammation, obesity, and metabolic disease. *Genome Medicine*, 8(1), 42. https://doi.org/10.1186/s13073-016-0303-2
32. Choudhary, P. R., Jani, R. D., & Sharma, M. S. (2018). Effect of raw crushed garlic (*Allium sativum* L.) on components of metabolic syndrome. *Journal of Dietary Supplements*, 15(4), 499–506. https://doi.org/10.1080/19390211.2017.1358233
33. NCD Risk Factor Collaboration. (2016). Trends in adult body-mass index in 200 countries from 1975 to 2014: A pooled analysis of 1698 population-based measurement studies with 19.2 million participants. *The Lancet*, 387(10026), 1377–1396. https://doi.org/10.1016/S0140-6736(16)30054-X
34. Darand, M., Darabi, Z., Yari, Z., Hedayati, M., Shahrbaf, M. A., Khoncheh, A., et al. (2019a). The effects of black seed supplementation on cardiovascular risk factors in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled clinical trial. *Phytotherapy Research*, 33(9), 2369–2377. https://doi.org/10.1002/ptr.6424
35. Darand, M., Darabi, Z., Yari, Z., Saadati, S., Hedayati, M., Khoncheh, A., et al. (2019b). *Nigella sativa* and inflammatory biomarkers in patients with nonalcoholic fatty liver disease: Results from a randomized, double-blind, placebo-controlled clinical trial. *Complementary Therapies in Medicine*, 44, 204–209. https://doi.org/10.1016/j.ctim.2019.04.014

36. Das Gupta, A., Das, S. N., Dhundasi, S. A., & Das, K. K. (2008). Effect of garlic (*Allium sativum*) on heavy metal-induced alteration of serum lipid profile in male albino rats. *International Journal of Environmental Research and Public Health*, 5(3), 147–151. https://doi.org/10.3390/ijerph2008050020
37. Datau, E. A., Wardhana, E. E., Surachmanto, E. E., Pandelaki, K., Langi, J. A., & Fias, W. (2010). Efficacy of *Nigella sativa* on serum free testosterone and metabolic disturbances in central obese male. *Acta Medica Indonesiana*, 42(3), 130–134.
38. Dias, T. (2013). White tea (*Camellia sinensis*): Antioxidant properties and beneficial health effects. *International Journal of Food Science, Nutrition and Dietetics*, 2(2), 19–26.
39. Drobiova, H., Thomson, M., Al-Qattan, K., Peltonen-Shalaby, R., Al-Amin, Z., & Ali, M. (2011). Garlic increases antioxidant levels in diabetic and hypertensive rats determined by a modified peroxidase method. *Evidence-Based Complementary and Alternative Medicine*, 2011, 703049. https://doi.org/10.1093/ecam/nep011
40. Dulloo, A. G., Jacquet, J., Solinas, G., Montani, J. P., & Schutz, Y. (2010). Body composition phenotypes in pathways to obesity and metabolic syndrome. *International Journal of Obesity*, 34(Suppl. 2), S4–S17. https://doi.org/10.1038/ijo.2010.234
41. Eidi, A., Eidi, M., & Esmaeili, E. (2006). Antidiabetic effect of garlic (*Allium sativum* L.) in normal and streptozotocin-induced diabetic rats. *Phytomedicine*, 13(9–10), 624–629. https://doi.org/10.1016/j.phymed.2005.09.010
42. El-Saber Batiha, G., Magdy Beshbishy, A., Wasef, L. G., Elewa, Y. H. A., Al-Sagan, A. A., Abd El-Hack, M. E., et al. (2020). Chemical constituents and pharmacological activities of garlic (*Allium sativum* L.): A review. *Nutrients*, 12(3), 872. https://doi.org/10.3390/nu12030872
43. Espinosa, C., González-Silvera, D., Pérez-Llamas, F., López-Jiménez, J. Á., & Zamora, S. (2015). Effect of long-term intake of white tea on acute oxidative stress in rats. *Nutrición Hospitalaria*, 32(2), 749–756. https://doi.org/10.3305/nh.2015.32.2.9270
44. Esser, N., Legrand-Poels, S., Piette, J., Scheen, A. J., & Paquot, N. (2014). Inflammation as a link between obesity, metabolic syndrome, and type 2 diabetes. *Diabetes Research and Clinical Practice*, 105(2), 141–150. https://doi.org/10.1016/j.diabres.2014.04.006
45. Fan, Y., & Pedersen, O. (2020). Gut microbiota in human metabolic health and disease. *Nature Reviews Microbiology*, 19, 55–71. https://doi.org/10.1038/s41579-020-0433-9
46. Ferrante, A. W., Jr. (2007). Obesity-induced inflammation: A metabolic dialogue in the language of inflammation. *Journal of Internal Medicine*, 262(4), 408–414. https://doi.org/10.1111/j.1365-2796.2007.01852.x
47. Gilani, A. U. H., Jabeen, Q., & Khan, M. A. U. (2004). A review of medicinal uses and pharmacological activities of *Nigella sativa*. *Pakistan Journal of Biological Sciences*, 7(4), 441–445.
48. Gondoin, A., Grussu, D., Stewart, D., & McDougall, G. J. (2010). White and green tea polyphenols inhibit pancreatic lipase in vitro. *Food Research International*, 43(5), 1537–1544. https://doi.org/10.1016/j.foodres.2010.04.029

49. Ha, A. W., Ying, T., & Kim, W. K. (2015). The effects of black garlic (*Allium sativum*) extracts on lipid metabolism in rats fed a high-fat diet. *Nutrition Research and Practice*, 9(1), 30–36. https://doi.org/10.4162/nrp.2015.9.1.30
50. Hase, T., Komine, Y., Meguro, S., Takeda, Y., Takahashi, H., Matsui, Y., et al. (2001). Anti-obesity effects of tea catechins in humans. *Journal of Oleo Science*, 50(7), 599–605. https://doi.org/10.5650/jos.50.599
51. Hashem, R. M., Mahmoud, M. F., El-Moselhy, M. A., & Soliman, H. M. (2008). Interleukin-10 to tumor necrosis factor-alpha ratio is a predictive biomarker in nonalcoholic fatty liver disease. *European Journal of Gastroenterology & Hepatology*, 20(10), 995–1001. https://doi.org/10.1097/MEG.0b013e3282fdf65f
52. Hibi, M., Takase, H., Iwasaki, M., Osaki, N., & Katsuragi, Y. (2018). Efficacy of tea catechin-rich beverages to reduce abdominal adiposity and metabolic syndrome risks in obese and overweight subjects: A pooled analysis of six human trials. *Nutrition Research*, 55, 1–10. https://doi.org/10.1016/j.nutres.2018.03.012
53. Hmza, A. J. A., Omar, E., Adnan, A., & Osman, M. T. (2013). *Nigella sativa* oil has significant repairing ability of damaged pancreatic tissue occurring in induced type 1 diabetes mellitus. *Global Journal of Pharmacology*, 7(1), 14–19. https://doi.org/10.5829/idosi.gjp.2013.7.1.7383